A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Lenvatinib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 31 Jul 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as unable to execute a contract agreement with the drug manufacturer.
- 30 Jul 2016 New trial record